S. Dubey

Concept: A randomised multicentre trial of first line chemotherapy comparing three weekly cabazitaxel versus weekly paclitaxel in HER2 negative metastatic breast cancer

J. Braybrooke, A. Hackshaw, S. Madhusudan, 2022, Breast.

Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer

A. Makris, S. Kuemmel, P. Schmid, 2019, JAMA oncology.

Abstract OT1-03-12: MANTA: A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer

A. Makris, S. Kuemmel, P. Schmid, 2016 .

1573 Amisulpride, a dopamine D2/D3-antagonist, prevents chemotherapyinduced nausea and vomiting (CINV) in patients receiving highly emetogenic cisplatin or anthracycline-cyclophosphamide regimens: A randomised, double-blind, placebo-controlled, dose-ranging trial

M. Ewertz, S. Chan, Y. Summers, 2015 .

Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled, dose-ranging trial

J. von Pawel, M. Ewertz, Y. Summers, 2018, Supportive Care in Cancer.

Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial.

A. Gadducci, A. Lissoni, S. Cosio, 2024, The Lancet. Oncology.